ESR1 and breast cancer: Medical records often indicated a longer tamoxifen protocol compared to the registry, as patients likely were switched to the five-year protocol as evidence emerged supporting longer adjuvant treatment.[37] As expected, a much greater percentage of the ER– group was assigned to systemic chemotherapy treatment, as the overall prognosis for this subset of breast cancer patients was lower, and fewer adjuvant treatment options existed.